Review of 2015 San Antonio Breast Cancer Symposium

doi:10.3877/cma.j.issn.1674-0807.2016.01.002

Abstract

Abstract:

This article selected some hot topics discussed in San Antonio Breast Cancer Symposium in 2015, including chemotherapy, neoadjuvant chemotherapy, molecular targeted therapy and immunotherapy for breast cancer patients, and briefly introduced several significant findings presented at the conference in order to provide references to medical staff of breast care and improve the standardization and normalization of breast cancer treatment in the future.

Key words: Breast neoplasms, Chemotherapy, adjuvant, Immunotherapy, Molecular targeted therapy

Jin Zhang, Jiayang Wei. Review of 2015 San Antonio Breast Cancer Symposium[J]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(01): 6-9.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2016.01.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2016/V10/I01/6

References 12

[1]	Liu FF, Shi W, Done SJ, et al. Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy [J].J Clin Oncol,2015,33(18):2035-2040.
[2]	Slamon D, Eiermann W, Robert N, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC-T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 +early breast cancer patients [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_1030&terms.
[3]	Toi M, Lee SJ,Lee ES,et al. A phase Ⅲtrial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X,JBCRG-04) [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_1229&terms.
[4]	von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66):a randomised phase 2 trial [J].Lancet Oncol,2014,15(7):747-756.
[5]	Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage Ⅱ-Ⅲtriple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) [J]. Ann Surg,2015,262(3):434-439.
[6]	No authors listed. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial [J]. JAMA Oncol, 2015,1(4):544.
[7]	Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumabbased adjuvant therapy in patients with HER2-positive breast cancer(ExteNET): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial [EB/OL]. [2016-01-05]. http:/ /www.sciencedirect.com/science/article/pii/S1470204515005513.
[8]	Boyraz B, Sendur MA, Aksoy S, et al. Trastuzumab emtansine(T-DM1) for HER2-positive breast cancer [J]. Curr Med Res Opin,2013,29(4):405-414.
[9]	Hein A, Lambrechts D, von Minckwitz G, et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase ⅢGeparQuinto study[J]. Int J Cancer,2015,137(12):2981-2988.
[10]	Vansteenkiste JF, Canon JL, Braud FD, et al. Safety and efficacy of Buparlisib (BKM120) in patients with PI3K pathway-activated nonsmall cell lung cancer:results from the phase ⅡBASALT-1 study [J].J Thorac Oncol,2015,10(9):1319-1327.
[11]	Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab(MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial [EB/OL]. [2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view.php? nu=SABCS15L_984&terms.
[12]	Adams S, Diamond J,Hamilton E,et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [EB/OL].[2016-01-05]. http:/ /www. abstracts2view. com/sabcs15/view. php?nu=SABCS15L_1208&terms.

[1]	Yang Li, Jinyu Cai, Xiaozhi Dang, Wanying Chang, Yan Ju, Yi Gao, Hongping Song. Application value of a deep learning-based model for generating strain elastography images using breast grayscale ultrasound images [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 563-570.
[2]	Collaboration Group，Breast Cancer Specialty Committee，Hebei Anti-Cancer Association Nursing. Expert consensus on nursing management of central venous access in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 321-329.
[3]	Chenlu Liu, Jie Liu, Fan Zhang, Caiying Yan, Qian Chen, Shuangqing Chen. Habitat analysis based on enhanced MRI radiomic features in predicting HER-2 expression in breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 339-345.
[4]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[5]	Lin Qiu, Jinhui Liu, Tuerhong Zumureti, Yuexin Ma, Xiaoling Leng. Diagnostic value of ultrasound radiomics in non-mass breast cancer in dense breasts [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 353-360.
[6]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[7]	Mengmeng Han, Xueyuan Feng, Ning Ma. A case of radial nerve injury after modified radical surgery for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 117-118.
[8]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[9]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[10]	Lingyan Wang, Chunhui Gao, Xueyuan Feng, Xinmiao Cui, Huan Liu, Wenming Zhao, Jinku Zhang. Application of circulating tumor cells in neoadjuvant and postoperative adjuvant therapy for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 630-633.
[11]	Linjuan Zhao, Jie Lv, Wensheng Wang, Demao Ma, Tao Hou. Study on the effect of ultrasound guided resection of stellate and cylindrical lactation preserving areas with staining marks [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 634-637.
[12]	Yi Lin, Wenlong Zhong, Kaiwen Li, Wang He, Tianxin Lin. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 15）: comprehensive treatment of metastatic bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 648-652.
[13]	Weizhou Wu, Qiongren Wang, Xiongyu Zhan, Mingxing Zheng, Yaxian Li. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 16): sarcomatoid renal cell carcinoma of the left kidney [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 525-529.
[14]	Weijie Chen, Xiaodong He. Progress in immunotargeted therapy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 763-768.
[15]	Changqian Wang, Tingting Lin, Yulu Ning, Yingjie Wang, Wenyong Tan. Recent advances in application of near-infrared photoimmunotherapy in cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 575-583.

Please choose a citation manager

Content to export